Clinical Evaluations of Clobetasone-17-Butyrae Ointment (Kindavate®) on the Various Facial Dermatitis

• Published in: Skin research Vol. 28; no. 1; pp. 74 - 81
• Main Authors: ISHII, Masamitsu, KOHNO, Takeshi, KITAJIMA, Junichi, TANII, Tsukasa, HOSOI, YOKO, SHOJI, Akinobu, YORIFUJI, Tokiko, ASAI, Yoshie, HAMADA, Toshio
• Format: Journal Article
• Language: English
• Published: Meeting of Osaka Dermatological Association 1986
• Subjects: clobetasone-17-butyrate-f; facial dermatitis; topical corticosteroid therapy
• ISSN: 0018-1390; 1884-541X
• DOI: 10.11340/skinresearch1959.28.74

Clinical efficacy and side actions of 0.05% clobetasone-17-butyrate ointment were evaluated on the various facial dermatitis. A total of 30 cases, i. e., 17 cases of atopic dermatitis, 4 cases of eczema infantum, 3 cases of seborrheic dermatitis, 2 cases of eczzema vulgare, 2 cases of actinic dermatitis and a case of pruritus cutaneus with eczematization, were examined for a variety of periods from 3 to 175 days. Although an average application period was relatively long 7 weeks, local side actions such as, skin atrophy, teleangiectasia, acne and rosacea-like dermatitis were not at all observed. Marked or moderate improvement was achieved in 28 out of the whole 30 cases (93%). This high efficacy and low side actions of this remedy indicate the high capability of safety application to the face where steroid side effect troubles tend to occur easily.